Advancing a class on top of statins
Investors & Media

Investor Overview

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>

NASDAQ | GEMP (Common Stock)

$9.10

 0.66 (6.76%)

High$9.56
Low$8.80
Volume44,538
Market Cap$103,778,490

01/23/18  12:06 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: GEMP.O.  Currently trading at $9.10 with a 52 week high of $21.59 and a 52 week low of $6.61.

Gemphire Completes Patient Enrollment in INDIGO-1 Trial in Severe Hypertriglyceridemia (SHTG) Patients

01/17/18

Read More

Gemphire Therapeutics Announces Initiation of its First NASH Proof-of-Concept Clinical Trial and its Differentiated NASH Program

12/21/17

Read More

Gemphire to Present at the Piper Jaffray and LD Micro Investor Conferences

11/22/17

Read More


There are currently no events scheduled.